MilliporeSigma
  • Characterization of chitin-metal silicates as binding superdisintegrants.

Characterization of chitin-metal silicates as binding superdisintegrants.

Journal of pharmaceutical sciences (2009-08-20)
Iyad Rashid, Nidal Daraghmeh, Mayyas Al-Remawi, Stephen A Leharne, Babur Z Chowdhry, Adnan Badwan
ABSTRACT

When chitin is used in pharmaceutical formulations, processing of chitin with metal silicates is advantageous, from both an industrial and pharmaceutical perspective, compared to processing using silicon dioxide. Unlike the use of acidic and basic reagents for the industrial preparation of chitin-silica particles, coprecipitation of metal silicates is dependent upon a simple replacement reaction between sodium silicate and metal chlorides. When coprecipitated onto chitin particles, aluminum, magnesium, or calcium silicates result in nonhygroscopic, highly compactable/disintegrable compacts. Disintegration and hardness parameters for coprocessed chitin compacts were investigated and found to be independent of the particle size. Capillary action appears to be the major contributor to both water uptake and the driving force for disintegration of compacts. The good compaction and compression properties shown by the chitin-metal silicates were found to be strongly dependent upon the type of metal silicate coprecipitated onto chitin. In addition, the inherent binding and disintegration abilities of chitin-metal silicates are useful in pharmaceutical applications when poorly compressible and/or highly nonpolar drugs need to be formulated.

MATERIALS
Product Number
Brand
Product Description

Supelco
Florisil® Adsorbent for Chromatography, 30-60 mesh
Supelco
Florisil® Adsorbent for Chromatography, 60-100 mesh
Sigma-Aldrich
Florisil®, 100-200 mesh
Supelco
Florisil®, PR grade, 60-100 mesh, coarse powder
Supelco
Florisil®, 100-200 mesh, fine powder
Supelco
Florisil®, for the determination of hydrocarbon acc. to ISO 9377-2
Supelco
Florisil®, <200 mesh, fine powder
Supelco
Florisil® PR, PR grade (analysis acc. to FDA)